Could Pin1 help us conquer essential hypertension at an earlier stage? A promising early-diagnostic biomarker and its therapeutic implications for the disease

Medical Hypotheses

Volumn 81, Issue 5, 2013, Pages 931-935

  Wang, Jing Zhang ^a   Li, Shu Rui ^b   Li, Ya Li ^b   Zhang, Yong Ze ^a   Zhang, Ting ^a   Zhao, Chao Xian ^a   Yao, Chun Xia ^a   Du, Lin Fang ^c  

^a HEBEI UNIVERSITY OF ENGINEERING   (China)

^b HANDAN CENTRAL HOSPITAL   (China)

^c SICHUAN UNIVERSITY   (China)

Author keywords

A ; AD; ENOS and iNOS; NO; PBMC; PPIase; TGF ; VEGF

Indexed keywords

NITRIC OXIDE; PEPTIDYLPROLYL ISOMERASE PIN1;

ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CATALYSIS; EARLY DIAGNOSIS; ENDOTHELIAL DYSFUNCTION; ESSENTIAL HYPERTENSION; HUMAN; NONHUMAN; PATHOGENESIS; PROTEIN FUNCTION; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

RATTUS;

AD; ALZHEIMER'S DISEASE; AMYLOID-BETA; AΒ; ENDOTHELIAL AND INDUCIBLE NITRIC OXIDE SYNTHASE, RESPECTIVELY; ENOS AND INOS; NITRIC OXIDE; NO; PBMC; PEPTIDYL-PROLYL CIS-TRANS ISOMERASE; PERIPHERAL BLOOD MONONUCLEAR CELLS; PPIASE; TGF-Β; TRANSFORMING GROWTH FACTOR-BETA; VASCULAR ENDOTHELIAL GROWTH FACTOR; VEGF;

AGE FACTORS; BIOLOGICAL MARKERS; HUMANS; HYPERTENSION; MODELS, BIOLOGICAL; NITRIC OXIDE SYNTHASE TYPE III; PEPTIDYLPROLYL ISOMERASE; VASODILATOR AGENTS;

EID: 84886803594     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2013.08.020     Document Type: Article

References (58)

1. Kearney P.M., Whelton M., Reynolds K., Muntner P., Whelton P.K., He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005, 365:217-223.
2. Rosales-Mendoza S. Can a plant-based vaccine treat hypertension?. Med Hypotheses 2012, 79:555-559.
3. Xu H., Oliveira-Sales E.B., McBride F., et al. Upregulation of junctional adhesion molecule-A is a putative prognostic marker of hypertension. Cardiovasc Res 2012, 96:552-560.
4. Zharikov S.I., Swenson E.R., Lanaspa M., Block E.R., Patel J.M., Johnson R.J. Could uric acid be a modifiable risk factor in subjects with pulmonary hypertension?. Med Hypotheses 2010, 74:1069-1074.
5. Ufnal M. Essential hypertension - is erroneous receptor output to blame?. Med Hypotheses 2012, 78:454-458.
6. Xi B., Wang Q., Pan H. Transforming growth factor-beta1 gene +869T/C, but not +915G/C polymorphism is associated with essential hypertension in a Chinese patient cohort. Mol Biol Rep 2012, 39:6107-6112.
7. Wang H.G., Wang J.L., Chang P., et al. Endothelial nitric oxide synthase gene polymorphisms and essential hypertension in Han Chinese. Genet Mol Res 2010, 9:1896-1907.
8. Palmirotta R., Ferroni P., Ludovici G., et al. VEGF-A gene promoter polymorphisms and microvascular complications in patients with essential hypertension. Clin Biochem 2010, 43:1090-1095.
9. Wang J.Z., Xi L., Zhu G.F., et al. The acidic pH-induced structural changes in Pin1 as revealed by spectral methodologies. Spectrochim Acta A Mol Biomol Spectrosc 2012, 98:199-206.
10. Wang J.Z., Lin T., Teng T., Xie S.S., Zhu G.F., Du L.F. Spectroscopic studies on the irreversible heat-induced structural transition of Pin1. Spectrochim Acta A Mol Biomol Spectrosc 2011, 78:142-147.
11. Wang J.Z., Zhang Y.H., Sun X.W., et al. Focusing on the structure and the function of Pin1: new insights into the opposite effects of fever on cancers and Alzheimer's disease. Med Hypotheses 2013, 81:282-284.
12. Liou Y.C., Zhou X.Z., Lu K.P. Prolyl isomerase Pin1 as a molecular switch to determine the fate of phosphoproteins. Trends Biochem Sci 2011, 36:501-514.
13. Lee T.H., Pastorino L., Lu K.P. Peptidyl-prolyl cis-trans isomerase Pin1 in ageing, cancer and Alzheimer disease. Expert Rev Mol Med 2011, 13:e21.
14. Chiasson V.L., Munshi N., Chatterjee P., Young K.J., Mitchell B.M. Pin1 deficiency causes endothelial dysfunction and hypertension. Hypertension 2011, 58:431-438.
15. Hermann M., Flammer A., Luscher T.F. Nitric oxide in hypertension. J Clin Hypertens (Greenwich) 2006, 8:17-29.
16. Ruan L., Torres C.M., Qian J., et al. Pin1 prolyl isomerase regulates endothelial nitric oxide synthase. Arterioscler Thromb Vasc Biol 2011, 31:392-398.
17. Erol A. Pin1 as a protector of vascular endothelial homeostasis. Hypertension 2012, 59:e14.
18. Kou R., Greif D., Michel T. Dephosphorylation of endothelial nitric-oxide synthase by vascular endothelial growth factor. Implications for the vascular responses to cyclosporin A. J Biol Chem 2002, 277:29669-29673.
19. Kim M.R., Choi H.S., Heo T.H., Hwang S.W., Kang K.W. Induction of vascular endothelial growth factor by peptidyl-prolyl isomerase Pin1 in breast cancer cells. Biochem Biophys Res Commun 2008, 369:547-553.
20. De Stefano A., Carlomagno C., Pepe S., Bianco R., De Placido S. Bevacizumab-related arterial hypertension as a predictive marker in metastatic colorectal cancer patients. Cancer Chemother Pharmacol 2011, 68:1207-1213.
21. Paduch R., Kandefer-Szerszen M. Transforming growth factor-beta1 (TGF-beta1) and acetylcholine (ACh) alter nitric oxide (NO) and interleukin-1beta (IL-1beta) secretion in human colon adenocarcinoma cells. In Vitro Cell Dev Biol-Animal 2009, 45:543-550.
22. Vural P., Degirmencioglu S., Erden S., Gelincik A. The relationship between transforming growth factor-beta1, vascular endothelial growth factor, nitric oxide and Hashimoto's thyroiditis. Int Immunopharmacol 2009, 9:212-215.
23. Lijnen P.J., Petrov V.V., Fagard R.H. Association between transforming growth factor-beta and hypertension. Am J Hypertens 2003, 16:604-611.
24. Li B., Khanna A., Sharma V., Singh T., Suthanthiran M., August P. TGF-beta1 DNA polymorphisms, protein levels, and blood pressure. Hypertension 1999, 33:271-275.
25. Nakano A., Koinuma D., Miyazawa K., et al. Pin1 Down-regulates transforming growth factor-beta (TGF-beta) signaling by inducing degradation of Smad proteins. J Biol Chem 2009, 284:6109-6115.
26. Ma S.L., Pastorino L., Zhou X.Z., Lu K.P. Prolyl isomerase Pin1 promotes amyloid precursor protein (APP) turnover by inhibiting glycogen synthase kinase-3beta (GSK3beta) activity: novel mechanism for Pin1 to protect against Alzheimer disease. J Biol Chem 2012, 287:6969-6973.
27. Driver J.A. Understanding the link between cancer and neurodegeneration. J Geriatr Oncol 2012, 3:58-67.
28. Pastorino L., Sun A., Lu P.J., et al. The prolyl isomerase Pin1 regulates amyloid precursor protein processing and amyloid-beta production. Nature 2006, 440:528-534.
29. Misiti F., Carelli-Alinovi C., Sampaolese B., Giardina B. Beta-amyloid decreases detectable endothelial nitric oxide synthase in human erythrocytes: a role for membrane acetylcholinesterase. Cell Biochem Funct 2012, 30:474-479.
30. Kenyon C.J. The genetics of ageing. Nature 2010, 464:504-512.
31. Blom J.W., de Ruijter W., Witteman J.C.M., et al. Changing prediction of mortality by systolic blood pressure with increasing age: the Rotterdam study. Age 2013, 35:431-438.
32. Meyerfreunda D., Goncalves C.P., Cunha R.S., Pereira A.C., Krieger J.E., Mill J.G. Age-dependent increase in blood pressure in two different Native American communities in Brazil. J Hypertens 2009, 27:1753-1760.
33. Gasowski J., Piotrowicz K. Breast cancer, age, and hypertension: a complex issue. Hypertension 2012, 59:186-188.
34. Jiang X., Castelao J.E., Yuan J.-M., et al. Hypertension, diuretics and antihypertensives in relation to bladder cancer. Carcinogenesis 2010, 31:1964-1971.
35. Elias M.F., Davey A. Midlife blood pressure, amyloid-beta, and risk for Alzheimer disease one more reason to treat hypertension. Hypertension 2012, 59:771-772.
36. Shah N.S., Vidal J.S., Masaki K., et al. Midlife blood pressure, plasma beta-amyloid, and the risk for Alzheimer disease: the Honolulu Asia Aging Study. Hypertension 2012, 59:780-786.
37. Iadecola C., Park L., Capone C. Threats to the mind aging, amyloid, and hypertension. Stroke 2009, 40:S40-S44.
38. Skoog I., Gustafson D. Update on hypertension and Alzheimer's disease. Neurol Res 2006, 28:605-611.
39. You Y., Deng J., Zheng J., et al. Functional polymorphisms in PIN1 promoter and esophageal carcinoma susceptibility in Chinese population. Mol Biol Rep 2013, 40:829-838.
40. Segat L., Pontillo A., Annoni G., et al. PIN1 promoter polymorphisms are associated with Alzheimer's disease. Neurobiol Aging 2007, 28:69-74.
41. Ma S.L., Tang N.L., Tam C.W., et al. A PIN1 polymorphism that prevents its suppression by AP4 associates with delayed onset of Alzheimer's disease. Neurobiol Aging 2012, 33:804-813.
42. Lu J., Yang L., Zhao H., et al. The polymorphism and haplotypes of PIN1 gene are associated with the risk of lung cancer in Southern and Eastern Chinese populations. Hum Mutat 2011, 32:1299-1308.
43. Bulbarelli A., Lonati E., Cazzaniga E., Gregori M., Masserini M. Pin1 affects Tau phosphorylation in response to A beta oligomers. Mol Cell Neurosci 2009, 42:75-80.
44. Lu P.J., Zhou X.Z., Liou Y.C., Noel J.P., Lu K.P. Critical role of WW domain phosphorylation in regulating phosphoserine binding activity and Pin1 function. J Biol Chem 2002, 277:2381-2384.
45. Ranganathan R., Lu K.P., Hunter T., Noel J.P. Structural and functional analysis of the mitotic rotamase Pin1 suggests substrate recognition is phosphorylation dependent. Cell 1997, 89:875-886.
46. Dietl K., Renner K., Dettmer K., et al. Lactic acid and acidification inhibit TNF secretion and glycolysis of human monocytes. J Immunol 2010, 184:1200-1209.
47. Lebedeva M.V., Stakhova T., Minakova E.G., Zaitseva L.I., Severova M.M., Pulin A.A. Endothelial function in patients with arterial hypertension and impaired uric acid metabolism. Vestn Ross Akad Med Nauk 2010, 44-46.
48. Demartini F.E., Cannon P.J., Stason W.B., Laragh J.H. Lactic acid metabolism in hypertensive patients. Science 1965, 148:1482-1484.
49. Wang J.Z., Lin T., Zhu G.F., Du L.F. Stability of Pin1 as revealed by thermal and spectroscopic studies. J Mol Struct 2010, 975:310-316.
50. Bailey M.L., Shilton B.H., Brandl C.J., Litchfield D.W. The dual histidine motif in the active site of Pin1 has a structural rather than catalytic role. Biochemistry 2008, 47:11481-11489.
51. Leung K.W., Tsai C.H., Hsiao M., et al. Pin1 overexpression is associated with poor differentiation and survival in oral squamous cell carcinoma. Oncol Rep 2009, 21:1097-1104.
52. Ayala G., Wang D.G., Wulf G., et al. The prolyl isomerase Pin1 is a novel prognostic marker in human prostate cancer. Cancer Res 2003, 63:6244-6251.
53. Fukuchi M., Fukai Y., Sohda M., et al. Expression of the prolyl isomerase Pin1 is a useful indicator of sensitivity to chemoradiotherapy in advanced esophageal squamous cell carcinoma. Oncol Rep 2009, 21:853-859.
54. Liu T.Z., Huang Y.C., Likhotvorik R.I., Keshvara L., Hoyt D.G. Protein Never in Mitosis Gene A Interacting-1 (PIN1) regulates degradation of inducible nitric oxide synthase in endothelial cells. Am J Physiol Cell Physiol 2008, 295:C819-C827.
55. Buharalioglu C.K., Korkmaz B., Cuez T., et al. Piroxicam reverses endotoxin-induced hypotension in rats: contribution of vasoactive eicosanoids and nitric oxide. Basic Clin Pharmacol Toxicol 2011, 109:186-194.
56. Calvert T.J., Chicoine L.G., Liu Y., Nelin L.D. Deficiency of mitogen-activated protein kinase phosphatase-1 results in iNOS-mediated hypotension in response to low-dose endotoxin. Am J Physiol Heart Circ Physiol 2008, 294:H1621-H1629.
57. Strunk V., Hahnenkamp K., Schneuing M., Fischer L.G., Rich G.F. Selective iNOS inhibition prevents hypotension in septic rats while preserving endothelium-dependent vasodilation. Anesth Analg 2001, 92:681-687.
58. Liu T., Schneider R.A., Hoyt D.G. Calpastatin is regulated by protein never in mitosis gene A interacting-1 (PIN1) in endothelial cells. Biochem Biophys Res Commun 2011, 414:581-586.